Massachusetts Eye and Ear named as first site for the study   CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10). LCA10 is caused by mutations... Read More